Immune checkpoint blockade: a common denominator approach to cancer therapy - Wikidata - awgldk - TriplyDB

Immune checkpoint blockade: a common denominator approach to cancer therapy

Immune checkpoint blockade: a common denominator approach to cancer therapy

http://www.wikidata.org/entity/Q28083981

about

Towards tumor immunodiagnostics A Mini-Review for Cancer Immunotherapy: Molecular Understanding of PD-1/PD-L1 Pathway & Translational Blockade of Immune Checkpoints The broken "Off" switch in cancer signaling: PP2A as a regulator of tumorigenesis, drug resistance, and immune surveillance Current status and perspectives in translational biomarker research for PD-1/PD-L1 immune checkpoint blockade therapy Survivin: a unique target for tumor therapy Overcoming Hypoxia-Mediated Tumor Progression: Combinatorial Approaches Targeting pH Regulation, Angiogenesis and Immune Dysfunction Chimeric antigen receptor T-cell therapy for solid tumors Bacteria in Cancer Therapy: Renaissance of an Old Concept Cytokine-Induced Modulation of Colorectal Cancer Cancer-Associated Immune Resistance and Evasion of Immune Surveillance in Colorectal Cancer Regulation of Natural Killer Cell Function by STAT3 Immune Evasion Strategies of Glioblastoma Clinical Options in Relapsed or Refractory Hodgkin Lymphoma: An Updated Review Novel technologies and emerging biomarkers for personalized cancer immunotherapy The Dichotomy of Tumor Exosomes (TEX) in Cancer Immunity: Is It All in the ConTEXt?Anti-Tumor Immunity in Head and Neck Cancer: Understanding the Evidence, How Tumors Escape and Immunotherapeutic Approaches Biomarkers in phase I-II chemoprevention trials: lessons from the NCI experience Melanoma: oncogenic drivers and the immune system Adoptive T-cell therapies for refractory/relapsed leukemia and lymphoma: current strategies and recent advances Muscle-invasive urothelial bladder cancer: an update on systemic therapy Engineering opportunities in cancer immunotherapy Lymphatic Vessels, Inflammation, and Immunity in Skin Cancer Predictive factors for immunotherapy in melanoma Fueling the engine and releasing the break: combinational therapy of cancer vaccines and immune checkpoint inhibitors Exploiting the Immunomodulatory Properties of Chemotherapeutic Drugs to Improve the Success of Cancer Immunotherapy Challenges and Opportunities for T-Cell-Mediated Strategies to Eliminate HIV Reservoirs Cancer Dormancy: A Regulatory Role for Endogenous Immunity in Establishing and Maintaining the Tumor Dormant State Immune Reactivation by Cell-Free Fetal DNA in Healthy Pregnancies Re-Purposed to Target Tumors: Novel Checkpoint Inhibition in Cancer Therapeutics Lessons from other diseases: granulomatous inflammation in leishmaniasis Rationale for a Multimodality Strategy to Enhance the Efficacy of Dendritic Cell-Based Cancer Immunotherapy.Differential Activity of Nivolumab, Pembrolizumab and MPDL3280A according to the Tumor Expression of Programmed Death-Ligand-1 (PD-L1): Sensitivity Analysis of Trials in Melanoma, Lung and Genitourinary Cancers.Prognostic impact of programmed cell death-1 (PD-1) and PD-ligand 1 (PD-L1) expression in cancer cells and tumor-infiltrating lymphocytes in ovarian high grade serous carcinoma PD-1 Blockade with Pembrolizumab in Advanced Merkel-Cell Carcinoma.The Role of TAM Family Receptors in Immune Cell Function: Implications for Cancer Therapy Combination Approaches with Immune-Checkpoint Blockade in Cancer Therapy Targeting Immune Regulatory Networks to Counteract Immune Suppression in Cancer High-content molecular profiling of T-cell therapy in oncology Spotlight on pembrolizumab in non-small cell lung cancer: the evidence to date Targeting immune checkpoints in malignant glioma Focus on Nivolumab in NSCLC

P2860

Q26738691-578B0B36-14F9-4D11-AA88-CF5D2B1A5BBD Q26738729-76F4E243-68D8-4661-BCA6-7827311D037D Q26739246-6E920BD6-B4E5-4560-AFAB-B94F2D5F36F8 Q26745516-910223E0-8BBE-409F-A977-BA8E4430755B Q26747332-E90176CF-023A-4211-867B-F4036B4DFB91 Q26749333-3638B372-31E8-4BB7-906D-11C713AC2E5D Q26750908-972246F9-E75F-448E-A889-73A3F1043314 Q26751222-33160FBF-7FEA-4FD0-AAE3-093911093A83 Q26752374-FB8D38E2-DF79-4A7A-9F6C-E9E4F96925A2 Q26752491-D9B67635-93EE-4B06-8E8D-9EFB3C71DB91 Q26752551-B5C212AC-CB20-4450-8A4E-3FE882E77176 Q26765855-BFF3BBEC-51B6-4917-B176-14BA38013BE8 Q26770716-51E7F9EE-C332-45AF-A8F3-5753104497B5 Q26770780-F0170B06-9767-484E-BEC5-FB431094CBFB Q26773307-A7366F84-05AE-4793-8164-EF2B23A465DA Q26774312-5E253DA9-2C4D-4FA2-8F02-9C8C501E0FD1 Q26774585-86C7F5F7-6705-4C64-A4E9-E08295553596 Q26775598-187CA330-9567-454F-9FFF-213714E1EC00 Q26775720-0E5DBFB1-F113-4BD5-A5C2-8695E608D0B3 Q26775780-8D35A8C2-9CC4-446B-99AF-6712D50F49C5 Q26776373-4244A810-7E00-4F0F-A9A8-98F6E3BD04DF Q26778332-9A54AAF9-1F29-4CCE-825A-81E49929A91E Q26778765-1C560251-564A-40E9-A52A-83BD5C35A1BE Q26778793-1A928DFB-665D-425D-BD30-8E813504901E Q26779184-A84B97E6-2067-4185-8E6C-FDC75BE4557C Q26781511-4780DC97-18E7-4E23-8891-DD592D7CB3F1 Q26782573-86B989EB-8190-4874-B2E0-3151D64ACB13 Q26784480-55359E93-94D6-44B4-8E5A-936FEBE29AAD Q27323278-E272236D-D5D8-4E01-9BBA-ABE1B167A087 Q27686800-8162CC07-7EBC-48F2-A14F-F40D5038EA39 Q27853176-135E494A-03AA-4D72-B41B-74724511F586 Q27853285-E85DA3D8-33E3-4CF9-8691-6346F3B05F1A Q27853379-A0FB44D5-23C8-4EF9-84CC-4A57FAD0CF71 Q27928010-4940B678-153E-4023-A9B4-74B8C0CD45C4 Q28066199-F0FCB580-7B59-4DBD-9CDB-2D7BA9534DA6 Q28066486-803A452F-1477-4B49-9761-A88228DC8CC0 Q28066792-134FEC69-0E6F-4E5F-AD3B-97241F69199E Q28067610-53DEEA4E-5FEE-4525-98EF-DD903CF056B0 Q28072012-8D578348-A610-4E8C-998B-0CD9637DFD3A Q28073759-096F4858-33C6-4051-A606-F78C3972C43E

P2860

Immune checkpoint blockade: a common denominator approach to cancer therapy

http://www.wikidata.org/entity/Q28083981

description

2015 nî lūn-bûn

@nan

2015 թուականի Ապրիլին հրատարակուած գիտական յօդուած

@hyw

2015 թվականի ապրիլին հրատարակված գիտական հոդված

@hy

2015年の論文

@ja

2015年論文

@yue

2015年論文

@zh-hant

2015年論文

@zh-hk

2015年論文

@zh-mo

2015年論文

@zh-tw

2015年论文

@wuu

name

Immune checkpoint blockade: a common denominator approach to cancer therapy

@ast

Immune checkpoint blockade: a common denominator approach to cancer therapy

@en

Immune checkpoint blockade: a common denominator approach to cancer therapy

@nl

type

label

Immune checkpoint blockade: a common denominator approach to cancer therapy

@ast

Immune checkpoint blockade: a common denominator approach to cancer therapy

@en

Immune checkpoint blockade: a common denominator approach to cancer therapy

@nl

prefLabel

Immune checkpoint blockade: a common denominator approach to cancer therapy

@ast

Immune checkpoint blockade: a common denominator approach to cancer therapy

@en

Immune checkpoint blockade: a common denominator approach to cancer therapy

@nl

P1433

Q28083981-B1C4BD3C-F554-496E-911E-01AB9A45A3BA

P1476

Q28083981-83AED90B-A864-4AFA-A291-B641CE903BEB

P2093

Q28083981-7564247E-003A-4CDA-94DF-B3BF81ED3F63

Q28083981-96437DB1-5191-4626-8BCD-937D2611FD94

Q28083981-EDF572A0-B913-4893-80F9-4F35FB6D9B17

P2860

Q28083981-00F8B469-2E34-49CF-8A9C-1E7B641DC291

Q28083981-0470CF52-023A-481D-935A-2AC64FAFD5DF

Q28083981-1214AF1E-AADA-4658-B69B-913760651994

Q28083981-1308496A-B66D-4605-A56E-BC7B30715AE5

Q28083981-1379B860-5325-4E33-9EC6-F48844F2049D

Q28083981-1380BC92-4B79-453F-B249-9D8043839CBF

Q28083981-140309BC-A568-4734-887D-923389B37469

Q28083981-17FEE352-5ACB-47D8-A3A5-1849762820D3

Q28083981-1ADDE110-10EA-4DF9-9DC8-CE0DE81E7512

Q28083981-1C6D1E89-064A-4020-875F-0F76BDA13D4E

P304

Q28083981-74D20062-E5AE-4D07-A5E1-79AB612D151B

P31

Q28083981-A7C8F947-F332-414D-80DF-C14AC9599E35

P3181

Q28083981-A54EC542-1C38-4C7C-99F4-0B36FA9ADBD8

P356

Q28083981-9DFECE6B-9637-4A2D-ADDD-9E58392FB223

P407

Q28083981-15FAA31A-B07C-4A59-8317-195F0398DD58

P433

Q28083981-5E6DF513-1426-4EB9-AA8F-489389C9BB9D

P478

Q28083981-5D27FE74-4DB0-42C3-98C7-06D6BECD4D43

P577

Q28083981-17AF44EC-7B22-48A3-B9AC-7995F3A93364

P698

Q28083981-3DFD8282-A7F0-4329-B582-30C1B80ADB9D

P932

Q28083981-F7FB90C3-6D5D-42EC-89CB-F775B629CC82

P3181

P356

J.CCELL.2015.03.001

P1433

P1476

Immune checkpoint blockade: a common denominator approach to cancer therapy

@en

P2093

Charles G. Drake

http://www.w3.org/2001/XMLSchema#string

Drew M. Pardoll

http://www.w3.org/2001/XMLSchema#string

Suzanne L. Topalian

http://www.w3.org/2001/XMLSchema#string

P2860

Role of lymphocyte activation gene-3 (Lag-3) in conventional and regulatory T cell function in allogeneic transplantation

B7-H1, a third member of the B7 family, co-stimulates T-cell proliferation and interleukin-10 secretion

B7-H3: a costimulatory molecule for T cell activation and IFN-gamma production

B7-DC, a new dendritic cell molecule with potent costimulatory properties for T cells

LAG-3, a novel lymphocyte activation gene closely related to CD4

The immunoreceptor TIGIT regulates antitumor and antiviral CD8(+) T cell effector function

CD28/B7 system of T cell costimulation

The surface protein TIGIT suppresses T cell activation by promoting the generation of mature immunoregulatory dendritic cells

Characterization of the major histocompatibility complex class II binding site on LAG-3 protein

CTLA-4 and PD-1 receptors inhibit T-cell activation by distinct mechanisms

P304

450-61

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P3181

38900

http://www.w3.org/2001/XMLSchema#string

P356

10.1016/J.CCELL.2015.03.001

http://www.w3.org/2001/XMLSchema#string

P407

P433

4

http://www.w3.org/2001/XMLSchema#string

P478

27

http://www.w3.org/2001/XMLSchema#string

P577

2015-04-13T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

25858804

http://www.w3.org/2001/XMLSchema#string

P932

4400238

http://www.w3.org/2001/XMLSchema#string